<img height="1" width="1" src="https://www.facebook.com/tr?id=414339248965737&amp;ev=PageView &amp;noscript=1">

Eyes on Research

Ophthalmic Clinical Trials: Addressing Barriers to Enrollment and Retention

20/20 Onsite

Clinical Trial Accessibility: Bridging the Gap for Underserved Populations

20/20 Onsite

Clinical Research Logistics: How Point-of-Need Execution Protects Ocular Endpoints

By 20/20 Onsite

Clinical research logistics in ophthalmic trials are not just about moving equipment or scheduling visits. They directly affect endpoint quality. When intraocular pressure (IOP), best corrected... Read More

What Clinical Trial Management Solutions Don't Cover: The Ocular Endpoint Execution Gap

By 20/20 Onsite

Ocular endpoints can pose challenges in otherwise well-managed clinical trials. IOP, BCVA, OCT, visual fields, and fundus imaging require trained ophthalmic personnel, calibrated equipment,... Read More

When Your Protocol Includes Ocular Endpoints: Why Ophthalmology Clinical Research Services Matter

By 20/20 Onsite

Ocular endpoints can become a failure point in otherwise well-designed clinical trials. When IOP measurements vary across sites, OCT imaging is not captured consistently, or BCVA assessments are not... Read More

Retina Clinical Trials: What Re-Acquisition in Retinal Imaging Is Really Costing Your Program

By 20/20 Onsite

Key Takeaways A failed OCT scan in retina clinical trials does not just cost a rescan. It costs a visit window, a deviation filing, and sometimes the patient. The invoice never shows full damage.... Read More

Ophthalmology Patient Engagement and Retention: Reducing Dropout Through Point-of-Need Execution

By 20/20 Onsite

In ophthalmology trials, dropout is often treated like an unfortunate reality. In practice, it is usually more predictable than teams assume and more preventable than protocols reflect. Read More

Ocular Hypertension in Clinical Trials: Protecting IOP Endpoints From Execution Risk

By 20/20 Onsite

In clinical trials that deal with ocular hypertension, intraocular pressure (IOP) is not just a measurement. It is often the primary determinant of regulatory credibility and treatment response... Read More

Ophthalmology CRO Selection: Protecting Ocular Endpoints From Operational Risk

By 20/20 Onsite

Selecting an ophthalmology CRO is fundamentally a risk decision. Sponsors and clinical operations leaders are not just choosing a vendor; they are choosing how ocular endpoints will be protected... Read More

Ophthalmology Clinical Trials: Why Sponsors Are Prioritizing This Therapeutic Area

By 20/20 Onsite

Ophthalmology Clinical Trials: Strategic Growth, Scientific Innovation, and Execution Risk for Sponsors Key Takeaways Aging populations and chronic disease growth are expanding the patient pool for... Read More